Abstract
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
| Original language | English |
|---|---|
| Pages (from-to) | 255-262 |
| Number of pages | 8 |
| Journal | 放射治療與腫瘤學 |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1994 |
| Externally published | Yes |
Fingerprint
Keywords
- Cisplatin
- 5-Fluorouracil
- 頑固性胃癌
- leucovorin
- Fluorouracil
Cite this
Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. / 陳榮楷; 吳秋文; 林增熙; 季匡華; 趙毅; 黃以信; 吳銘芳; 陳育民; 劉敏; 彭汪嘉康; 李壽東; 雷永耀.
In: 放射治療與腫瘤學, Vol. 1, No. 3, 1994, p. 255-262.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients
AU - 陳榮楷, null
AU - 吳秋文, null
AU - 林增熙, null
AU - 季匡華, null
AU - 趙毅, null
AU - 黃以信, null
AU - 吳銘芳, null
AU - 陳育民, null
AU - 劉敏, null
AU - 彭汪嘉康, null
AU - 李壽東, null
AU - 雷永耀, null
PY - 1994
Y1 - 1994
N2 - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
AB - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
KW - Cisplatin
KW - 5-Fluorouracil
KW - 頑固性胃癌
KW - leucovorin
KW - Fluorouracil
KW - Cisplatin
KW - 5-Fluorouracil
KW - Leucovorin
KW - Refractory Gastric Cancer
KW - Fluorouracil
U2 - 10.6316/TRO/199401(3)255
DO - 10.6316/TRO/199401(3)255
M3 - Article
VL - 1
SP - 255
EP - 262
JO - 放射治療與腫瘤學
JF - 放射治療與腫瘤學
SN - 1023-988x
IS - 3
ER -